Partner With OneThree

To generate new insights to accelerate your internal R&D or identify new candidates to fill your pipeline.
Together we can discover new medicines at an unprecedented scale.

Our Partners and Collaborators

Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships
Partnerships

Testimonials

” OneThree’s AI platform helped answer direct mechanistic questions on our top drug candidates, opened up new therapeutic opportunities, helped solve problems that we had been working on for years, and potentially saved several years of additional work. I expect that the approach OneThree Biotech is taking will be integral to the future of drug discovery and development. “

Partnerships
Josh Allen, Ph.D
Chief Science Officer

” The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection. We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach. “

Partnerships
Syed Kazmi
CEO, Jubilant Therapeutics

” The AI platform of OneThree is ingenius. Not only did it help us identify a new microtubule inhibitor with activity in eribulin-resistant breast cancer model that was refractory to all known MT inhibitors, but it also provided new connections between seemingly unrelated drug classes suggesting shared mechanism of action or shared side effect profile. Deployment of this platform in pharmaceutical companies and large clinical cooperative groups will have a tremendous impact in drug development.”

Partnerships
Paraskevi (Evi) Giannakakou, PhD
Director of Laboratory Research (Heme/Onc) & Professor of Pharmacology at Weill Cornell
Learn more
Explore our publications, news, case studies and blogs to learn more.
Contact us
Please contact us to discuss your specific needs!

Partnership Areas

Partnerships

Target Discovery

  • Identifying novel disease targets 
  • Identifying targets that are essential for disease progression in a given indication or patient population (think in-silico CRISPR screening)
  • Uncovering genetic interactions (such as synthetic lethality or sickness) that could be exploited therapeutically 
  • Identifying targets that contribute to organ or patient specific toxicities 

Lead Identification

  • Identifying new compounds or combinations that could modulate a given disease phenotype or treat resistant patients 
  • Pinpointing small molecules that bind (or not bind) a specific set of targets
  • Identifying synergistic combinations for a given genotype or patient subpopulation
Partnerships
Partnerships

Mechanism of Action Discovery

  • Uncovering on and off target bindings for a given small molecule
  • Identifying activated or modulated pathways following treatment with a given drug
  • Providing insights into the pathways or targets involved in patient or organ specific adverse event

ADME/Toxicity

  • Predicting the likelihood of organ specific adverse events (such as drug induced liver injury or pleural effusion) for a given compound
  • Identifying contributing factors into an observed toxic effects (for instance, differentiating between structure vs target derived toxicities)
  • Predicting blood/brain barrier permeability
Partnerships
Partnerships

Therapeutic Positioning and Biomarkers 

  • Identify top therapeutic opportunities for assets in development or shelved assets
  • Uncover biomarkers of response that could be used to select optimal patient subgroups
  • Identify other drugs that could be paired with a given compound for synergistic combination therapies